





Campbell, A.D., Lawn, S., McGarry, L.C., Welch, H.C., Ozanne, B.W., and 
Norman, J.C. (2013) P-rex1 cooperates with PDGFRβ to drive cellular 


































Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
P-Rex1 Cooperates with PDGFRb to Drive Cellular
Migration in 3D Microenvironments
Andrew D. Campbell1., Samuel Lawn1.¤, Lynn C. McGarry1, Heidi C. Welch2, Bradford W. Ozanne1,
Jim C. Norman1*
1 Beatson Institute for Cancer Research, Bearsden, Glasgow, United Kingdom, 2 The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom
Abstract
Expression of the Rac-guanine nucleotide exchange factor (RacGEF), P-Rex1 is a key determinant of progression to
metastasis in a number of human cancers. In accordance with this proposed role in cancer cell invasion and metastasis, we
find that ectopic expression of P-Rex1 in an immortalised human fibroblast cell line is sufficient to drive multiple migratory
and invasive phenotypes. The invasive phenotype is greatly enhanced by the presence of a gradient of serum or platelet-
derived growth factor, and is dependent upon the expression of functional PDGF receptor b. Consistently, the invasiveness
of WM852 melanoma cells, which endogenously express P-Rex1 and PDGFRb, is opposed by siRNA of either of these
proteins. Furthermore, the current model of P-Rex1 activation is advanced through demonstration of P-Rex1 and PDGFRb as
components of the same macromolecular complex. These data suggest that P-Rex1 has an influence on physiological
migratory processes, such as invasion of cancer cells, both through effects upon classical Rac1-driven motility and a novel
association with RTK signalling complexes.
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Introduction
The ability of tumour cells to escape their local environment
and form distant metastases is a hallmark of cancer [1,2]. Key
players in this process are the RhoGTPase family of molecules,
which have long been associated with the regulation of cancer cell
morphology, motility and invasion [3]. Unlike related members of
the RasGTPase family, reports of activating mutations of
RhoGTPases, such as Rac1, RhoA or Cdc42 are relatively rare
in cancer. Nonetheless, there is ample evidence for their altered
function, often through aberrant activity of regulatory molecules
such as RhoGEFs (guanine nucleotide exchange factors), some of
which were originally isolated as transforming factors in cancer
cells [4,5].
P-Rex1 (PI(3,4,5)P3-dependent Rac exchanger 1) is a Rac-
specific member of the Dbl family of RhoGEFs – multidomain
proteins which catalyse dissociation of GDP from inactive
RhoGTPase molecules, and facilitate activation through loading
with free intracellular GTP [6,7]. The presence of approximately
60 independent Dbl family GEFs permits intricate spatial and
temporal regulation of the RhoGTPases [7]. Further complexity is
added by upstream regulators of GEF activity, such as P-Rex1,
whose activity is in turn synergistically stimulated by interaction
with the phospholipid PI(3,4,5)P3 and bc subunits of the
heterotrimeric G-proteins [6,8,9]. Since the oncogenic capacity
of the Dbl gene product was isolated and shown to mediate GEF
enzymatic activity for the RhoGTPase Cdc42 [10], numerous
GEFs have been implicated in the progression of cancer.
Specifically, expression of P-Rex1 itself has been identified as
important factor in tumour cell invasion and metastasis in a
number of cancer models, both in vivo and in vitro[11–14].
Regulation of P-Rex1 through association with PI(3,4,5)P3im-
plicates upstream signalling pathways involving receptor tyrosine
kinases (RTKs), phosphatidyl inositol 3-kinase (PI3K) and PTEN
in P-Rex1 driven Rac1 activity [15]. Indeed, it has previously been
demonstrated that generation of PI(3,4,5)P3 by PI3K downstream
of RTK activation can result in increased P-Rex1 activity [8,13].
In this report, we elucidate an additional regulatory mechanism,
where cooperation between P-Rex1 and the PDGFRb receptor
tyrosine kinase is both necessary and sufficient to drive migration
of fibroblasts in 3D models of cellular invasion. Given that
expression of P-Rex1 appears to be a key determinant in
formation of distant metastases in a number of models, including
melanoma, breast and prostate cancer, we propose that in certain
contexts PDGFRb and P-Rex1 may act as a novel, pro-invasive
signalling module.
Results
P-Rex1 Overexpression Drives Morphological Changes in
a Human Fibroblast Cell Line
Stable, retroviral expression of myc-epitope tagged guanine
nucleotide exchange factor (GEF) constructs in an immortalised
human fibroblast cell line was readily achieved and could be
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detected by immunoblotting for either P-Rex1 or the appropriate
epitope tag (Figure 1A). This exogenous expression of P-Rex1
generated a flattened and rounded morphology, characterised by
dramatic formation of lamellipodia and dorsal membrane ruffles
(Figure 1B). Stable exogenous expression of Tiam1, a related GEF
of the Dbl family, to similar levels as P-Rex1 (Figure 1A) resulted
in similar morphological changes (Figure 1B). In both P-Rex1 and
Tiam1 expressing cells, the observed ruffling morphology was very
similar to that previously reported upon expression of Rac1G12V, a
constitutively active mutant of the small GTPase molecule, Rac1
[16]. There was a concurrent reduction in the intensity of actin
based stress fibres in favour of peripheral actin-rich structures such
as lamellipodia and dorsal ruffles, in P-Rex1 and Tiam1
expressing fibroblasts, as indicated by TRITC-phalloidin staining
of filamentous actin (Figure 1B, arrowheads). In contrast,
fibroblasts expressing a control vector or a line expressing a
GEF-dead mutant of P-Rex1incapable of catalysing GTP
exchange (E56A, N238A – known henceforth as P-Rex1-GD)
[9], exhibited no appreciable morphological changes when
compared to the parental line (Figure 1B).
The morphological changes associated with GEF expression
were quantified using automated, high-throughput imaging. Stable
expression of P-Rex1 or Tiam1 resulted in a statistically significant
1.5 fold increase in mean width to length ratio of the cells
compared to vector control over a sample set of more than 7,500
cells per condition (Figure 1C). These results were mirrored by
quantification of a second independent criterion, dorsal ruffling,
with its mean intensity increasing by 1.4 fold in both P-Rex1 and
Tiam1 expressing cells, when compared to vector control
(Figure 1D). Importantly, expression of P-Rex1-GD did not alter
either of these quantitative indices of cell morphology, by
comparison to vector control (Figure 1C, D). Furthermore, it
was noted that the morphological changes observed upon stable,
ectopic expression of P-Rex1 in this cell culture model were
dependent upon P-Rex1 expression, and could be reversed
through transfection with a P-Rex1-specific siRNA oligonucleo-
tide, though not through mock treatment or transfection with a
non-targetting siRNA oligonucleotide (Figure 1C, D).
Expression of P-Rex1 Influences the Migration of Human
Fibroblasts on 2D Substrates and in 3D
Microenvironments
As modulation of RhoGTPase activity is commonly associated
with altered cellular motility, we measured the migration of GEF-
expressing or control fibroblasts initially on a 2D substrate. Cells
were grown to confluence, the monolayer wounded using a 200 ml
pipette tip and migration into the wound monitored by digital
time-lapse microscopy in combination with live cell tracking
(Figure 2A). Expression of P-Rex1 was associated with extension of
large polarised lamellipodia and extensive dorsal ruffling at the
leading edge, which were not observed in Tiam1 expressing
fibroblasts (Figure 2A, Supplemental movies S1–S4). Quantifica-
tion of these movies indicated that P-Rex1 drove a modest, but
significant difference in migration speed, where mean velocity was
increased from 0.354 mm min21 to 0.415 mm min21 (Figure 2B).
Importantly, the expression of P-Rex1 resulted in a marked (1.7
fold) increase in forward migratory index (FMI) (Figure 2C), a
measure of migration perpendicular to the wound edge, and a 1.5
fold increase in migratory persistence (Figure 2D). Conversely,
expression of Tiam1, although able to drive ruffling and cell shape
changes (Figure 1), did not alter migratory persistence or FMI of
cell migrating into scratch-wounds (Figure 2). Moreover, the GEF-
dead mutant of P-Rex1, P-Rex-GD, did not alter any of these
quantitative indices of cell migration (Figure 2).
P-Rex1 expression has been associated with tumour cell
invasion and progression to metastasis in a number of cancer
models in vivo. We have, therefore, investigated whether P-Rex1
overexpression was able to alter invasive-type migration of
fibroblasts into plugs of Matrigel. Strikingly, while parental
fibroblasts or those expressing a control vector did not invade
towards a chemoattractant gradient of serum, more than 40%
of P-Rex1-expressing cells migrated a distance of more than
45 mm into Matrigel, whereas P-Rex1-GD was ineffective in this
regard (Figure 3A, B). Moreover, transient knockdown of P-
Rex1 with siRNA oligonucleotides reduced invasion into
Matrigel by at least 4-fold (Figure 3C, D). Moreover, P-Rex1-
driven invasiveness was dependent upon GEF activity, as P-
Rex1-GD expressing cells were unable to invade into Matrigel
under identical conditions (Figures 2 and 3). Importantly, the
related RacGEF Tiam1 was unable drive invasion of fibroblasts
into Matrigel (Figure 3A). These data indicate that while P-
Rex1 and Tiam1 are capable of increasing cellular ruffling and
altering cell shape, only P-Rex1 is linked to the cell’s migratory
machinery in a way that drives cell migration in both 2D and
3D contexts.
P-Rex1 Driven Morphological Changes and Cellular
Migration Requires a Factor that is Present in Serum
In serum-containing culture conditions, overexpression of P-
Rex1 drives changes in fibroblast morphology and migration.
However, following serum-starvation, P-Rex1 expressing cells
revert to a state reminiscent of control fibroblasts (Figure 4A).
Indeed, high throughput imaging indicated that serum starvation
of P-Rex1 expressing cells reduced the mean ruffle intensity to that
of vector control cells (Figure 4B), and the mean cellular width/
length ratio was reduced by 1.4 fold, again to a value similar to
vector control (Figure 4B). Consistent with this, the invasive
potential of P-Rex1 expressing fibroblasts was dependent upon the
presence of a chemoattractant serum gradient (Figure 4C). Indeed,
upon the imposition of a 10% gradient of serum across a plug of
growth factor-depleted Matrigel, approximately 18% of P-Rex1
expressing fibroblasts penetrate more than 45 mm into the matrix.
Conversely, if the serum concentration was the same both above
and below the Matrigel plug, or if the gradient was reversed then
P-Rex1 expressing cells were unable to invade into the Matrigel
(Figure 4C).
We therefore sought to identify the serum factor responsible
for supporting P-Rex1-dependent invasiveness. Many serum
components that have previously been associated with RhoGT-
Pase-driven cell migration (such as epidermal growth factor
(EGF) and lysophosphatidic acid (LPA)) did not support the
invasiveness of P-Rex1 expressing fibroblasts when applied as a
gradient across a plug of Matrigel (not shown). However, a
gradient of PDGF-BB (0–50 ng/ml) was equally capable to
drive the invasion of P-Rex1 expressing fibroblasts into Matrigel
as was a 0–10% gradient of serum (Figure 4D). Importantly, a
PDGF gradient had little effect on control fibroblasts, suggesting
that P-Rex1 and PDGF signalling collaborate to drive invasive
migration. As recent reports have detailed an association
between Neuregulin/ErbB signalling and P-Rex1 activation
[12,13], we sought to compare the ability of Heregulin/NRG1
and PDGF-BB to support P-Rex1-driven fibroblast invasiveness.
In these experiments, 0–0.1 nM or 0–1 nM gradients of PDGF-
BB drove 1.4 and 2.4-fold increases respectively in invasive
migration. By contrast, the same concentrations of Heregulin/
NRG1 did not drive P-Rex1-dependent invasion. (Figure 4E).
P-Rex1, PDGFR and Invasion
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Figure 1. RacGEF expression alters the morphology of immortalised human fibroblasts. (A,B) Parental (Tif), and control vector (pLHCX) or
RacGEF expressing telomerase-immortalised human fibroblasts were subject to immunofluorescent labelling with myc-epitope specific primary
P-Rex1, PDGFR and Invasion
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A Physical Association between P-Rex1 and PDGFRb
Given the requirement for PDGF in P-Rex1 mediated invasion,
we sought to confirm through a combination of confocal imaging
and immunoprecipitation whether P-Rex1 and receptors for
PDGF were physically connected. Fibroblasts expressing either a
vector control or myc-tagged RacGEFs (myc-P-Rex1 or myc-
Tiam1) were transiently transfected with a GFP-tagged fusion
protein of the PDGF receptor b polypeptide (PDGFRb) [17], and
visualised by confocal microscopy. PDGFRb-GFP colocalised
closely with each of P-Rex1, P-Rex1 GD and Tiam1 in ruffling
structures which are characteristic of active GEF expression
(Figure 5A, arrows). It is intriguing that PDGFRb and P-Rex1 GD
also appear to co-localise, although limited regions of membrane
ruffling which are located at the poles of the spindle-shaped P-
Rex1 GD expressing cells (Figure 5A arrowheads).
To determine whether P-Rex1 and PDGFRs were associated
physically with one another, we immunoprecipitated myc-tagged
P-Rex1 and Tiam1 from fibroblasts and probed for the presence of
the PDGFRb. This revealed that PDGFRb associated with P-
Rex1, but not with Tiam1 (Figure 5B). Moreover, PDGFRb was
strongly associated with P-Rex1 GD indicating that P-Rex’s GEF
activity was not required for this interaction (Figure 5B).
Furthermore, P-Rex1 and PDGFRb coimmunoprecipitated
equally well in serum-starved or serum-replete cells indicating
that activation of the receptor was not necessary for the complex to
form (Figure 5C). Although we are able consistently to
coimmunoprecipitate PDGFRb with P-Rex1, we have found that
a similar physical association between PDGFRa and P-Rex1
cannot be reproducibly demonstrated in these fibroblasts.
P-Rex1 Mediated Invasion Requires PDGFRb
As PDGF-BB has high affinity for and can induce both homo-
and heterodimerisation of the PDGF receptor polypeptides a and
b [18,19], we sought to examine the contribution of PDGFRa and
PDGFRb to P-Rex1 dependent migratory phenotypes in this cell
type. Western blotting indicated that we were able to selectively
suppress expression of PDGFRa and PDGFRb either alone or in
combination using siRNA (Figure 6A). siRNA of PDGFRb
strongly suppressed invasive migration of P-Rex1 expressing
fibroblasts into Matrigel toward a gradient of serum, whereas
knockdown of PDGFRa was ineffective in this regard (Figure 6A).
These findings were consolidated by rescue experiments with
PDGFR null mouse embryonic fibroblasts, a cell culture model in
which the genes for both PDGFRa and PDGFRb have been
disrupted [20], and which do not express endogenous P-Rex1
(Figure 6B). Initially, human PDGFRb or a control vector were
stably expressed in PDGFR 2/2 MEFs, which following several
rounds of selection, were subjected to a further round of retroviral
infection with human P-Rex1 or secondary vector control
constructs. This approach yielded four cell lines stably expressing
PDGFRb or P-Rex1 either individually or in combination
(Figure 6B), and allowed for the determination of the individual
contribution of P-Rex1 and PDGFRb to invasive migration in this
model system. PDGFR 2/2 fibroblasts were poorly invasive and
expression of P-Rex1 did not alter this. Moreover, expression of
PDGFRb in mouse fibroblasts that do not express P-Rex1 only
drove invasion to a very limited extent. However, the combined
expression of P-Rex1 with PDGFRb dramatically increased the
ability of mouse fibroblasts to invade into Matrigel (Figure 6B).
Taken together, these data demonstrate a close spatial, physical
and functional relationship between P-Rex1 and PDGFRb in the
migration of fibroblasts through 3D microenvironments.
Having described a functional and physical association between
P-Rex1 and PDGFRb in human fibroblasts, we next sought to
assess the relationship between these proteins in a cell type that
expresses them endogenously. As we have previously reported that
P-Rex1 plays a key role in melanoma progression [21], we
screened a number of melanoma cell lines for the combined
expression of P-Rex1 and PDGFRb. In this way we identified the
WM852 melanoma line as one which expresses detectable levels of
P-Rex1 and PDGFRb and which is amenable to gene silencing
with specific siRNA oligonucleotides (Figure 7A). siRNA of either
P-Rex1 or PDGFRb dramatically reduced the invasive migration
of WM852cells into growth factor-reduced Matrigel plugs, when a
gradient of 10% FBS supplemented with 5 ngml21 PDGF-BB was
used as a chemoattractant (Figure 7B, C).
Inhibition of PDGFR or its Downstream Signalling
through PI3K Perturbs P-Rex1 Mediated Migratory
Phenotypes
Although we have found that disruption of PDGFRb expression
by siRNA silencing or genetic deletion opposes P-Rex1 mediated
cellular invasion, it was clear that neither the presence of serum
nor activation of the receptor was required for coimmunopreci-
pitation of P-Rex1 and PDGFRb (see Figure 5C). We, therefore,
addressed whether pharmacological perturbation of PDGFR
activation would have similar effects upon P-Rex1 mediated
migration and invasion as does siRNA or genetic depletion of the
receptor.
We found that treatment of P-Rex1-expressing fibroblasts with
inhibitors of either PDGFR (PDGFRi; 5 mM) or PI3K (PI-103,
1 mM) was sufficient to oppose signalling downstream of PDGFR,
as assessed by western blotting for phosphorylation of Akt at
Thr473; a well-established read-out of activity of the PI3K
signalling axis (Figure 8A). Having established the ability of these
inhibitors to oppose PDGFR signalling, we determined their
impact on the migratory behaviour of P-Rex1-expressing fibro-
blasts in scratch-wound assays. Pharmacological inhibition of
PDGFRb had no significant effect on migratory velocity, but
PDGFRi had a small and statistically significant effect on the
forward migratory index and migratory persistence (Figure 8C–D,
supplementary movies S5 & S6). More strikingly, inhibition of the
PI3K pathway with PI-103 significantly decreased the migratory
velocity, forward migratory index and persistence of P-Rex1
expressing fibroblasts moving across plastic surfaces (Figure 8C–D,
supplementary movies S5 & S7).
Subsequently, we examined the effect of inhibition of PDGFRb
or PI3K on invasion of P-Rex1-expressing fibroblasts through
Matrigel. Inhibition of either the PDGFR family or PI3K strongly
inhibited the ability of P-Rex1-expressing fibroblasts to migrate
into Matrigel toward a gradient of FBS (0–10%). (Figure 8B).
Taken together, these data indicate that the ability of P-Rex1 to
monoclonal and alexafluor-488 conjugated secondary antibodies, and counterstained with TRITC conjugated phalloidin (B). Serial optical sections
were captured through confocal microscopy, and these images combined to form a 2D projection of fluorescence intensity throughout the cell.
Expression of the myc-tagged RacGEF constructs was confirmed by immunoblotting with both myc-epitope and target-specific primary antibodies
(A). (C,D) Control vector (pLHCX) or RacGEF expressing fibroblasts were stained as for (B), and the mean cellular width/length ratio (C) and intensity of
cellular dorsal ruffling (D) was determined by means of high-throughput imaging of a sample set of more than 7,500 cells per condition. The same
criteria were used to quantify the effect of P-Rex1 knockdown in P-Rex1 stable expressors (Bars 20 mm, ***P,0.0005, Mann-Whitney rank sum test).
doi:10.1371/journal.pone.0053982.g001
P-Rex1, PDGFR and Invasion
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e53982
Figure 2. P-Rex1 expression promotes persistent migration on a 2D substrate. (A) Parental (Tif), and control vector (pLHCX) or RacGEF
expressing fibroblasts emerging from the migratory front of scratch-wound assays were analysed using time-lapse microscopy, with images captured
every 10 minutes over a period of 18 hours. Individual cells were manually tracked and the migratory path of representative cells depicted as track
plots. The phase contrast images correspond to the initial frame from the supplementary movies S1–S4 as indicated. (B-D) Influence of RacGEF
expression on migratory behaviour was quantified by determination of mean cellular velocity (B), forward migratory index (C) and migratory
persistence (D). (Bars 50 mm, **P,0.005, Mann-Whitney rank sum test).
doi:10.1371/journal.pone.0053982.g002
P-Rex1, PDGFR and Invasion
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Figure 3. Expression of P-Rex1 promotes invasive behaviour of human fibroblasts. (A) Invasive migration of parental (Tif) and control
vector (Tif pLHCX) orRacGEF expressing immortalised human fibroblasts into Matrigel plugs was determined by inverted invasion assay. Serial optical
sections of Calcein-AM stained invasive cells were captured at 15 mm intervals by confocal microscopy and depicted as a montage of successive
sections at increasing depth from left to right, as indicated. Invasive migration was quantified by measurement of fluorescence intensity of cells
penetrating the matrix to a depth of 45 mm and beyond, and expressed as a percentage of the total fluorescence intensity of all cells within the assay.
(B) Invasive migration of P-Rex1 expressing immortalised human fibroblasts transfected with non-targeting control or P-Rex1-specific siRNA
oligonucleotides, with quantification as above (6SEM, ***P,0.0001 Unpaired t-test, 3 independent experiments).
doi:10.1371/journal.pone.0053982.g003
P-Rex1, PDGFR and Invasion
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drive both invasion into Matrigel and to support persistent on
plastic surfaces requires the function of signalling pathways
downstream of PDGFR.
Discussion
P-Rex1 is an exchange factor for the RhoGTPase molecule
Rac1, which has been implicated in progression to metastasis in a
number of cancer models [11–14]. Through ectopic expression of
P-Rex1 in cell culture models, we have identified a close physical
and functional relationship between P-Rex1 and the receptor
tyrosine kinase PDGFRb during the acquisition of invasive cellular
migration in vitro.
P-Rex1 is a well-established upstream regulator of RhoGTPase
signalling [6,9,22]. In our hands, as in prior reports, ectopic
overexpression of the RacGEF P-Rex1 or the related molecule,
Tiam1 results in morphological changes in immortalised human
fibroblasts [6,23,24]. These phenotypic changes are characteristic
of increased Rac1 activity [16], and suggest that expression of P-
Rex1 or Tiam1 influences the balance of RhoGTPase signalling.
Importantly, these alterations to cell shape could not be driven by
expression of a catalytically inactive mutant P-Rex1 molecule
(E56A, N238A), suggesting dependence upon inherent GEF
activity. The morphological changes reported in this study are
truly robust, as more than 7,500 cells per condition were assayed,
utilising a high throughput imaging system and two independent
Figure 4. P-Rex1 requires a factor present in serum in order to drive alterations in cell shape and invasion; PDGF can substitute for
serum to drive invasion of P-Rex1 expressing cells. (A) P-Rex1 expressing fibroblasts cultured under normal growth conditions or serum-
starved for 12 hours were labelled as for Figure 1A above. (B) High throughput imaging was used to quantify the ruffle intensity and mean cellular
width/length ratio of P-Rex1 expressing fibroblasts in the presence and absence of serum. (C) The requirement for a serum gradient in the invasive
migration of P-Rex1 expressing fibroblasts was determined using an inverted invasion assay as for Figure 3A. (D) The invasive migration of vector
control (pLHCX) or P-Rex1 expressing fibroblasts into Matrigel in the absence or presence of a serum (0–10%) or PDGF-BB (0–50 ng ml21) gradient
was assayed and quantified as for Figure 3B (6SEM, ***P,0.0005, Mann-Whitney rank sum test, 3 independent experiments). (E) The comparative
invasive migration of P-Rex1 expressing fibroblasts into Matrigel in the absence or presence of gradients of PDGF-BB or NRG1 was assayed and
quantified as in Figure 3B (6SEM, ***P,0.0005 Mann-Whitney rank sum test, 3 independent experiments).
doi:10.1371/journal.pone.0053982.g004
Figure 5. Association of P-Rex1 with PDGFRb from immortalised human fibroblasts. (A) Control vector (pLHCX) or myc-RacGEF expressing
immortalised human fibroblasts were transfected with GFP-tagged PDGFRb and plated onto glass cover slips. Cells were fixed and the myc-tagged
RacGEFs were stained by immunofluorescent labelling with an antibody recognising the myc-epitope followed by AlexaFluor-555 conjugated
secondary antibodies. (B, C) Myc-tagged RacGEFs were stably expressed in immortalised human fibroblasts. The cells were then grown in serum-
containing medium (B) or serum-starved for 18 hr (right hand lanes in (C)) prior to lysis in a buffer containing 0.15% Tween-20. Myc-tagged RacGEFs
were immunoprecipitated from lysates using an antibody recognising the myc-epitope, and immunoisolated material was probed for the presence of
PDGFRb by immunoblotting.
doi:10.1371/journal.pone.0053982.g005
P-Rex1, PDGFR and Invasion
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morphological criteria. Thus, we can say objectively and with
confidence that active P-Rex1 and Tiam1 drive morphological
adaptation in human fibroblasts. Importantly, even when subject-
ed to such detailed quantitative analysis, it is clear that both P-
Rex1 and Tiam1 induce alterations to cell shape and ruffling that
Figure 6. PDGFRb is required for invasive migration of P-Rex1 expressing human fibroblasts. (A) Invasion of P-Rex1 expressing human
fibroblasts transfected with non-targeting siRNAs (siControl) or those targetting PDGFRa or PDGFRb,either alone or in combination, was assayed and
quantified as for Figure 3. (B) Embryonic fibroblasts from PDGFRa/b 2/2 mice were stably transfected with P-Rex1 or PDGFRb, either alone or in
combination. Invasion was determined as for Figure 3. (6SEM, *P,0.05, **P,0.005 Mann-Whitney rank sum test, 3 independent experiments).
doi:10.1371/journal.pone.0053982.g006
P-Rex1, PDGFR and Invasion
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are indistinguishable from one an another, and entirely consistent
with the ability of these two molecules to activate Rac.
When one analyses cell migration, the phenotypes induces by P-
Rex1 and Tiam1 are quite distinct. In scratch-wound assays, P-
Rex1 drove a significant, GEF-dependent increase in mean velocity,
persistence and forward migratory index of cells at the migratory
front of the wound [25]. However, no change in the migratory
behaviour of Tiam1 expressing cells was observed, despite clear
alterations in the morphology of sparsely cultured non-migrating
cells. This implies that a generalised increase in RacGEF activity is
not sufficient in itself to influence migratory behaviour and that P-
Rex1 has a particular role in this regard. Consistent with previously
described Tiam1 driven formation of Rac1 dependent cell-cell
contacts [26,27], we observe loss of refractile morphology of Tiam1
expressing fibroblasts under brightfield microscopy at high cell
densities which hints at altered cell to cell adhesion (Figure 2A).
Taken together, these studies indicate that different functions can be
ascribed to the two Rac GEFs of the present study - with Tiam1
primarily influencing cell:cell adhesion, whilst P-Rex1 is a powerful
promoter of cellular migration.
The earliest characterisation of P-Rex1 described a synergistic
regulation through association with the phospholipid PI(3,4,5)P3 and
bc subunits of the heterotrimeric G-proteins [6,9], indicating that it
is potentially capable of responding to signalling inputs generated
downstream of both G-protein coupled receptors and RTKs.
Moreover, these studies indicate that P-Rex1 may be recruited to
the plasma membrane by association with the PI(3,4,5)P3 produced
by growth factor receptor signalling. This said, our observation of a
physical association between P-Rex1 and an RTK (PDGFRb)
occurs in serum-starved cells indicates that regulated production of
PI(3,4,5)P3 is not a prerequisite for P-Rex1 recruitment cellular
membrane compartments. Additionally, P-Rex1-GD co-immuno-
precipitates efficiently with PDGFRb indicating that Rac activation
and the cytoskeletal changes occurring downstream of this are not
required for recruitment of P-Rex1 to PDGFRb.
In addition to the physical association between P-Rex1 and
PDGFRb, there is also a close functional relationship that is not
shared by Tiam1. Here we identify PDGF to be a serum
component that is both necessary and sufficient for P-Rex1 driven
migration and chemotaxis in a 3D microenvironment. Further-
more, we have used siRNA to show that this is mediated primarily
via PDGFRb and does not require PDGFRa. Furthermore, in
fibroblasts from mice in which the genes for PDGFRa and b have
been disrupted, expression of PDGFRb is sufficient to restore P-
Rex1-driven migration towards a serum gradient. Taken together,
these results indicate that PDGFRb, and not PDGFRa is a major
contributor to P-Rex1 ‘‘activation’’ in regard of invasive cell
migration in the context of our culture model. Subsequent
chemical inhibition of the PDGFR family in P-Rex1 expressing
fibroblasts also demonstrates that an active signalling axis exists
Figure 7. Expression of P-Rex1 and PDGFRb are required for invasive migration of WM852 melanoma cells. (A) Immunoblot showing
depletion of P-Rex1 or PDGFRb following transfection of cells with non-targeting control or siRNA oligonucleotides directed against P-Rex1 or
PDGFRb. (B,C) Invasive migration of WM852 cells into Matrigel following transfection with siRNA oligonucleotides targeting P-Rex1 or PDGFb was
determined as for Fig. 3A. In (C), panels have been appended to demonstrate the adherence of the WM852 cells to the lower surface (LS) of the
transwell.(6SEM, ***P,0.0005 Mann-Whitney rank sum test, 3 independent experiments).
doi:10.1371/journal.pone.0053982.g007
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Figure 8. Chemical inhibition of PDGFR signalling alters the migratory behaviour of P-Rex1 expressing cells in both 2D and 3D
environments. (A) Following a period of serum starvation, P-Rex1 expressing fibroblasts were stimulated with PDGF-BB, in the presence and
absence of DMSO control or chemical inhibitors as indicated. Cells were the lysed and the levels of P-Rex1 and PDGFRb were determined by Western
P-Rex1, PDGFR and Invasion
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involving PDGFR and P-Rex1, whereby specific loss of PDGFR
activity while maintaining protein expression, negatively affects P-
Rex1-dependent migratory behaviour both on a 2D substrate and
in 3D. Furthermore, similar observations made following inhibi-
tion of PI3K serve to highlight the importance of phosphatidyl
inositide signalling in regulation of P-Rex1 activity.
There is a strong correlation between P-Rex1 expression and
progression to metastasis in a number of cancer models[11–14].
The observation therefore, that expression of this single RacGEF
was sufficient to drive a dramatic increase in invasive migration in
3D matrices in vitro was particularly striking. Furthermore,
evidence exists to suggest that a functional relationship between
P-Rex1 and PDGFRb as described here may be a contributing
factor to cancer progression in vivo. The first suggestion of an
association arose in a genetic screen to identify key factors in
glioma progression in vivo, which highlighted PREX1 as a gene
which cooperates with PDGF signalling to promote metastasis
[28,29]. Moreover, in light of our recent description of P-Rex1 as
a key driver of melanoma progression in vivo [14], it is noteworthy
that a common mechanism of acquired resistance to novel
therapeutic kinase inhibitors in BRAFV600E driven melanoma is
upregulation of PDGFRb [30,31]. Indeed, we present data which
demonstrates that in vitro invasive migration of a human melano-
ma derived cell line, WM852, is dependent upon expression of
both P-Rex1 and PDGFRb.
In addition to their contribution to malignant growth in certain
cancer cell types, the PDGF receptors and autocrine PDGF
signalling are critical drivers of recruitment and growth of non-
transformed cells, such as pericytes, vascular smooth muscle cells
and stromal fibroblasts to the tumour site. These can in turn
contribute both to tumour growth and vascularity. It is therefore
important to note that through the in vitro experimentation
detailed here, we examine tumour cell autonomous effects of
PDGFR stimulation, in particular in the context of P-Rex1
mediated cellular migration, and do not consider the role of the
PDGF signalling axis on survival or growth of stromal cells in an
extant tumour in vivo. By way of example, while silencing of
PDGFRb negatively affects in vitro migratory behaviour in
individual cell lines, a number of publications have indicated that
mono- or combination therapies incorporating inhibition of
PDGFRs in vivo can result in a more aggressive invasive or
metastatic disease [32–35]. This appears at least in part due to a
stromal response, where negative effects upon both pericyte
growth and migration, can lead to poor pericyte coverage on
nascent blood vessels, resulting in a ‘‘leaky’’ tumour vasculature,
more susceptible to intravasation [33,35,36] Moreover, such
therapies may have a similar systemic effect, resulting in a more
conducive vascular environment for extravasation and subsequent
metastasis at a distant site [32].
It seems that the relationship between P-Rex1 and PDGFRb may
have direct relevance to tumour progression, and further studies to
reveal the details of the complex formed between these two important
signalling proteins and how they collaborate to direct cell migration
will be necessary to determine whether components of this pathway
can be targetted to oppose cancer progression and metastasis.
Materials and Methods
Cell Culture
hTERT immortalised human foetal fibroblasts (Tif cells) [37]
and PDGFR nullizygous mouse embryonic fibroblasts (‘‘F’’ cells)
[20] and their derivatives were maintained in DMEM (Invitrogen
Life Technologies Ltd.) supplemented with 10% foetal calf serum
(Biowest S.A.S.) and 200 mM L-Glutamine. ‘‘F’’ cells were the kind
gift of Prof. Andrius Kazlauskas of the Schepens Eye Institute,
Boston. WM852 melanoma cells were maintained as previously
reported [38], and were the kind gift of Professor Lional LaRue of
the Institut Curie, Orsay, Paris.
Stable Overexpression of P-Rex1/Tiam1 Constructs
pcDNA3.1-myc-Tiam1 was the kind gift of Dr. Angeliki Maliri
(Paterson Institute for Cancer Research, Manchester, UK).
pLNCX2-PDGFRa and pLXSN-PDGFRb were the kind gift of
Professor Andrius Kazlauskas (Schepens Eye Research Institute,
Boston, USA). Stable cell lines expressing exogenous PDGFRb,
myc-epitope tagged human P-Rex1 or Tiam1 constructs were
generated by retroviral infection using the modified Retro-X
retroviral expression system (Clontech Ltd.). High-titre, replica-
tion-incompetent retroviral particles encoding the mRNA of
interest were produced in either Phoenix Ampho or Eco packaging
lines (Orbigen) as appropriate, with transfer the coding region of
interest, along with a selectable marker achieved by subsequent
infection of target lines. Pooled cell lines stably expressing the
construct of interest were isolated by selection with the appropriate
antibiotic over multiple passages. Faithful expression of the protein
of interest was determined by immunodetection with both epitope
tag specific and protein specific primary antibodies.
Antibodies, Drugs and Recombinant Proteins
Rabbit polyclonal antibody raised against human P-Rex1
(HPA001927) and mouse monoclonal antibodies specific to b-actin
(clone AC-15, A1978) and b-tubulin (clone TUB2.1, T4026) were
obtained from Sigma-Aldrich Ltd. Mouse monoclonal antibodies
specific for the Myc-epitope tag (clone 9B11, 2276S) and PDGFRb
(clone 2B3, 3175S) were obtained from Cell Signalling Technology/
New England Biolabs UK. PDGFR inhibitor III (521232) was
obtained from Merck and PI-103 (2930) was from Tocris
Bioscience. Recombinant human EGF (AF-100-15) was obtained
from Peprotech EC Ltd, recombinant human PDGF-BB (P3201),
and NRG1 (SRP3055) were obtained from Sigma-Aldrich Ltd.
siRNA Treatments
Transient knockdown of target proteins was achieved through
consecutive rounds of liposome-mediated transfection with the
appropriate siRNA oligonucleotides, 48 hours apart. Liposomal
transfection reagent (301702, HiPerFect, Qiagen Ltd.), non-
targetting control oligonucleotides (1027281, AllStars Negative
Control, sequence not provided), P-Rex1 specific (SI00692391,
Hs_PREX1_1_HP, CCACATGATGATGAACAAGAA) and
Rac1 specific (SI02655051, Hs_RAC1_6_HP, sequence not
provided) oligonucleotides were obtained from Qiagen Ltd.
blotting. The activity of the PI3K/Akt axis was determined by Western blotting for Akt which was phosphorylated at Thr473. (B) Quantification of the
invasive migration of P-Rex1 expressing fibroblasts into Matrigel in the presence and absence of DMSO, PDGFRi (5 mM) or PI-103 (1 mM) as indicated
(6SEM, ***P,0.0005 Mann-Whitney rank sum test, 3 independent experiments). (C) P-Rex1 expressing fibroblasts emerging from the migratory front
of scratch-wound assays in the presence and absence of DMSO PDGFRi (5 mM) or PI-103 (1 mM) were analysed using time-lapse microscopy, with
images captured every 10 minutes over a period of 18 hours. Individual cells were manually tracked and the migratory path of representative cells
depicted as track plots. The phase contrast images correspond to the initial frame from the supplementary movies S5–S7 as indicated. (D-F) Influence
of chemical inhibition on migratory behaviour was quantified as in Figure 2 by determination of mean cellular velocity (D), forward migratory index
(E) and migratory persistence (F). (Bars 50 mm, *P,0.05, ***P,0.0005, Mann-Whitney rank sum test).
doi:10.1371/journal.pone.0053982.g008
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Oligonucleotides specific for PDGFRa (D-003162-09,
GGCCUUACUUUAUUGGAUU), PDGFRb (D-003163-06,
GGAAUGAGGUGGUCAACUU) and an appropriate non-
targetting control (D-001810-10) were obtained from Dharmacon
Ltd. Faithful silencing of the appropriate protein of interest was
determined by immunoblotting. Briefly, cells were lysed on ice in
50 mM Tris-HCl pH 6.8, 10% (v/v) glycerol and 1% (w/v) SDS,
supplemented with protease inhibitor (#78410, ThermoScientific)
and phosphatase inhibitor (P2850, Sigma-Aldrich Ltd.) cocktails.
Cell lysates were passed through a 26-gauge needle three times
and cell debris removed by centrifugation at 10,0006g and 4uC
for 10 minutes. These lysates were then denatured by boiling for
10 minutes in LDS buffer (Invitrogen Life Technologies Ltd.)
under reducing conditions. Proteins of interest were then resolved
by SDS-PAGE and detected with specific antibodies.
Scratch-Wound Assay and Timelapse Microscopy
Confluent monolayers of fibroblasts were seeded onto 6-well
tissue culture dishes and linear scratches made with a sterile 200 ml
pipette tip. These cells were incubated under normal tissue culture
conditions until cells at the wound edge began to migrate (,
4 hrs), and timelapse images were captured every 10 minutes for
18 hours. Imaging was performed with the X10 objective
(Axiovert S100, Carl Zeiss MicroImaging, Inc) in a controlled
atmosphere of 5% CO2 at 37˚C. Cell tracking was performed with
the Manual Tracking plugin for the ImageJ software platform and
mean velocity, persistence and forward migratory index were
calculated with the associated Chemotaxis and Migration Tool plugin
(http://rsb.info.nih.gov/ij/).
Inverted Invasion Assay
Inverted invasion assays were performed as previously described
[39]. In brief, Matrigel protein matrix (BD bioscience) was allowed
to polymerise in Transwell permeable inserts (Corning Ltd.) over
30 minutes at 37uC. The inserts were inverted and cells seeded
directly onto the filter surface. After 3 hours at 37uC, the inserts
were placed in serum-free tissue culture medium in 24-well plates,
and media containing the appropriate chemoattractant placed
above the Matrigel matrix. In the case of siRNA mediated
transient knockdown experiments, invasion assays were prepared
24 hours after the second round of lipofection. In the case of
inhibitor studies, drug or DMSO was included at the appropriate
concentration in both chemoattractant and serum-free media, and
as a component of the Matrigel matrix. Furthermore, in these
studies inserts were transferred to fresh serum-free tissue culture
medium containing the appropriate drug or control at 24 and 48
hours. In all assays, at 72 hours post-seeding, invasive cells which
had entered the Matrigel were stained with the fluorescent live-cell
dye Calcein-AM, visualised through confocal microscopy of
optical sections obtained in the z-plane at 15 mm intervals, and
quantified with the ImageJ Area Calculator plugin.
Immunoprecipitations
Human fibroblasts expressing constructs of interest were lysed in
IP-lysis buffer (200 mM NaCl, 75 mM Tris-HCl pH 7, 7.5 mM
EDTA, 7.5 mM EGTA, 0.15% (v/v) Tween-20, supplemented with
protease and phosphatase inhibitor cocktails. Cell lysates were
cleared as described above. Dynal magnetic beads conjugated to
sheep anti-mouse IgG (Invitrogen Life Technologies Ltd.), pre-
blocked with a solution of 1% (w/v) BSA in PBS, were bound to anti-
myc epitope or isotype matched control monoclonal (IgG2a, Sigma)
antibodies. Antibody bound beads were subsequently incubated in
1 ml of a 0.25 mgml21 lysate solution for 2 hours at 4uC with
constant rotation. Unbound proteins were removed from the beads
by extensive washing in lysis buffer, and specifically associated
proteins were eluted through incubation in lysis buffer supplemented
with 1% SDS for 10 minutes. Eluted proteins were resolved by SDS-
PAGE and detected by immunoblotting as described above.
Immunofluorescent Imaging of Fixed Specimens
Immunofluorescent staining of fixed cell specimens was per-
formed as described previously [40]. Briefly, cells were seeded at the
appropriate density onto coverglass, or in the case of high-
throughput imaging, into individual wells of a glass-bottomed 24-
well tissue culture plate (Iwaki Ltd.), 24 hours prior to fixation. Cells
were washed in PBS, and fixed with a 30 minute incubation in a 3%
(w/v) solution of paraformaldehyde in PBS, followed by permea-
bilisation with 0.25% (v/v) Triton-x-100 in PBS for 5 minutes, both
at room temperature. Non-specific antibody binding was blocked
with incubation in a 5% (w/v) BSA in PBS. Primary and secondary
antibody incubations were carried out in a 0.1% (w/v) solution of
BSA in PBS for 1 hour each at room temperature, separated by
3610 minute washes in a solution of 0.05% (v/v) Tween-20 and
150 mM NaCl in PBS. The antibody and drug concentrations used
were as follows –9B11 anti-myc epitope, 1/1000 (0.8 mgml21),
AF488 conjugated goat anti-mouse secondary, 1/200 (10 mgml21),
TRITC-conjugated phalloidin, 1/40 (5 Uml21) and DAPI 1/500
(100 ngml21). Stained coverslips were applied to slideglass with
Hydromount mounting media (National Diagnostics Ltd.), supple-
mented with 2.5% DABCO (Sigma-Aldrich Ltd.) as an anti-
oxidant/anti-fade agent. Cells mounted on slideglass were analysed
with a Zeiss LSM710 upright laser-scanning confocal microscope
(Carl Zeiss MicroImaging Ltd.). Specimens prepared for high
throughput imaging were stored in PBS at 4uC until needed.
High-Throughput Imaging
Imaging and analysis was performed with a high-throughput
Operetta fluorescent microscopy platform and Harmony image
analysis software (Perkin Elmer Ltd). Briefly, fibroblasts were
cultured in a multiwell-dish format and processed for immunoflu-
orescent staining as described above. Fluorescent cells were detected
through fluorescence intensity in either the A488 (AF488-anti-myc)
channel, or A546 (TRITC-phalloidin) channel, and individual
width/length ratio determined. Dorsal membrane ruffles present in
an outer ring region defined at 20% of the distance from the cell
edge to its centre were detected using a texture analysis algorithm,
whereby fluorescence intensity in ruffle structures was again
detected in either the A488 (AF488-anti-myc) channel, or A546
(TRITC-phalloidin) channel and subsequently normalised to
background fluorescence (i.e. fluorescence not ascribed to ruffles).
Supporting Information
Movie S1 Movement of 1 pLHCX vector control ex-
pressing fibroblasts into a scratch-wound.
(MOV)
Movie S2 Movement of pLHCX-myc-P-Rex1 expressing
fibroblasts into a stratch-wound.
(MOV)
Movie S3 Movement of pLHCX-myc-P-Rex1 GD ex-
pressing fibroblasts into a scratch-wound.
(MOV)
Movie S4 Movement of pLHCX-myc-Tiam1 expressing
fibroblasts into a scratch-wound.
(MOV)
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Movie S5 Movement of DMSO-treated human fibro-
blasts into a scratch-wound.
(MOV)
Movie S6 Movement of PDGF receptor inhibitor
(PDGFRi III, 5 mM)-treated human fibroblasts into a
scratch-wound.
(MOV)
Movie S7 Movement of PI-103 (1 mM)-treated human
fibroblasts into a scratch-wound.
(MOV)
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